Three significant pathways were identified–FGFR3 signaling in chondrocyte proliferation and terminal differentiation, nanoparticle-mediated activation of receptor signaling, and MYCN to transcriptional activation–each of which shows mechanistic or therapeutic relevance to IDH-wildtype gliomas. This evidence concerns the gene FGFR3 and central nervous system cancer.